Fabrazyme (agalsidase beta) — HCPCS J0180

Fabry disease therapy class comparison FDA verified May 2026

Three FDA-approved options in the US. Replagal (agalsidase alfa) is approved in Europe but NOT in the US.

Three therapies are FDA-approved for Fabry disease, with very different billing infrastructure. Choose the right comparator before quoting Fabrazyme.

Dosing & vial math FDA label verified May 2026

From the FDA Fabrazyme prescribing information (BLA 103979, pediatric expansion 2018).

Standard dosing

• 1 mg/kg IV every 2 weeks (lifelong)
• Initial infusion: max rate 0.25 mg/min (~15 mg/hour) — runs 2–4 hours
• If well-tolerated, infusion rate may be increased in subsequent infusions per label
• Adult and pediatric (≥2 years per 2018 FDA labeling expansion)
• 1 mg = 1 unit — bill the actual mg administered + JW for any discarded mg
• Typical adult: 26 doses/year (q2wk × 52 weeks)

Vial math — why JW is the rule, not the exception

Fabrazyme ships in two vial sizes: 5 mg and 35 mg lyophilized single-dose vials. Dosing is weight-based (1 mg/kg). Most patient weights cannot be matched exactly with the 5/35 mg combinations — the result is partial-vial waste on most infusion days.

Worked example — first-year billing for a 70 kg adult Fabry patient

Premedication protocol Standard of care May 2026

Not formally required by the FDA label but routinely used to mitigate infusion-associated reactions.

Approximately half of Fabrazyme patients experience infusion-associated reactions (IARs) including chills, fever, headache, fatigue, nausea, paresthesia, and pruritus. Antibody formation is common — most patients seroconvert (develop IgG anti-agalsidase beta antibodies) within 3–6 months and may experience worsened reactions or reduced efficacy as titers rise. Premedication is standard of care in most US infusion centers.

NDC reference FDA NDC Directory verified May 2026

Administration codes CPT verified May 2026

Fabrazyme is enzyme replacement therapy — non-chemo therapeutic IV codes apply.

Modifiers CMS verified May 2026

JW — routine on Fabrazyme claims

Fabrazyme ships in fixed 5 mg and 35 mg vials and dosing is weight-based, so partial-vial waste is common. JW reports the discarded portion of a single-dose vial. Bill JW with the actual discarded units on a separate claim line — admin line for the units administered (with JZ if the math truly produces zero waste), waste line for the discarded units (with JW). Wasted drug is reimbursable but must be reported.

JZ — only when zero waste

Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. For Fabrazyme this is uncommon but possible (e.g., a 70 kg patient using exactly two 35 mg vials). One of JZ or JW must be on every J0180 claim.

Modifier 25 — same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the infusion (e.g., genetics or cardiology consultation unrelated to infusion administration). Routine pre-infusion clinical assessment is bundled.

340B modifiers (JG, TB)

For 340B-acquired Fabrazyme, follow your MAC's current 340B modifier policy. Fabrazyme's price point makes 340B savings substantial for eligible covered entities — verify enrollment and modifier requirements with your 340B program coordinator.

ICD-10-CM by organ system FY2026 verified May 2026

Primary code is E75.21 for Fabry disease. Add secondary codes for documented organ involvement to support medical necessity.

Site of care & place of service Verified May 2026

UnitedHealthcare and Aetna run aggressive site-of-care UM for high-cost ERTs. Both have published site-of-care policies that steer Fabrazyme out of HOPD after the patient is stable on therapy. Home infusion is increasingly common for established Fabry patients — document tolerability before transitioning sites of care.

Claim form field mapping Sanofi 2025

From Sanofi Patient Connection coding & coverage guidance for J0180.

Payer policy snapshot Reviewed May 2026

All major payers require Fabry diagnostic confirmation (enzyme assay + GLA mutation analysis) and specialist consultation in the PA submission.

Step therapy

Generally NOT required — Fabrazyme is FDA-approved for Fabry disease and most payers do not require step therapy through other Fabry treatments. Some payers may require evaluation for Galafold amenability (in patients with amenable GLA missense mutations) before approving Fabrazyme, because Galafold is oral and substantially cheaper. Document the assay result (amenable vs non-amenable) in the PA.

Reauthorization cadence

Fabry disease is lifelong, but most payers require annual reauthorization. Submit updated organ-function labs (cardiac MRI/echo, eGFR, urine ACR), continued specialist supervision, and clinical response documentation (Mainz Severity Score Index or equivalent) at each reauth.

Elfabrio vs Fabrazyme — emerging payer dynamics Verified May 2026

Elfabrio (pegunigalsidase alfa-iwxj, J0219, Chiesi/Protalix) was FDA-approved May 2023 as an alternative ERT for Fabry disease. Same q2wk IV cadence and 1 mg/kg dose, but PEGylation extends the plasma half-life and is designed to reduce antibody response. Elfabrio's BALANCE phase 3 trial (NEJM 2023) demonstrated non-inferiority to Fabrazyme on annualized eGFR slope.

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.

Coverage

No NCD specific to agalsidase beta. Coverage falls under MAC LCDs for biologics + the generic drug-coverage framework. All MACs cover J0180 for FDA-approved indication (Fabry disease) with documented diagnostic confirmation (low α-Gal A enzyme activity and/or pathogenic GLA mutation) and appropriate ICD-10 (E75.21 primary + organ-involvement secondaries).

Code history

• J0180 — permanent code, "Injection, agalsidase beta, 1 mg" — in effect since shortly after the April 2003 FDA approval (BLA 103979). Pediatric labeling (≥2 years) added in 2018.

Patient assistance — Sanofi Patient Connection Sanofi verified May 2026

• Sanofi Patient Connection: 1-800-745-4447 / sanofipatientconnection.com — benefits investigation, prior authorization assistance, appeal support, free-product programs for eligible uninsured/underinsured patients
• Fabrazyme Patient Support: Sanofi maintains Fabry-disease-specific case managers as part of Sanofi Patient Connection — ask for the rare-disease team when calling
• Commercial copay assistance: available for eligible commercially-insured patients (excludes Medicare, Medicaid, federal program patients)
• Patient assistance program (PAP): free product for uninsured / underinsured patients meeting income requirements
• Foundations (for Medicare patients): refer to PAN Foundation, HealthWell, National Organization for Rare Disorders (NORD) — verify open Fabry-disease funds quarterly; rare-disease funds open and close on short notice
• Web: fabrazyme.com / sanofipatientconnection.com

Common denials & how to fix them

Frequently asked questions

What is the HCPCS code for Fabrazyme?

Fabrazyme (agalsidase beta) is billed under HCPCS J0180 — "Injection, agalsidase beta, 1 mg." Each milligram equals one billable unit, so a typical 70 mg dose (70 kg patient at 1 mg/kg) is billed as 70 units administered. Because Fabrazyme ships in fixed 5 mg and 35 mg single-dose vials and dosing is weight-based, partial-vial waste is the rule, not the exception, and the discarded mg must be billed on a separate JW line.

How many units do I bill for a typical Fabrazyme dose?

Bill the actual mg administered. A 70 kg adult at 1 mg/kg = 70 mg = 70 units of J0180 with JZ (no waste in this scenario, using two 35 mg vials). For weight-driven waste (e.g., 67 kg using two 35 mg vials = 70 mg drawn, 67 mg administered, 3 mg discarded) bill 67 units on the admin line (with JZ on admin line) and 3 units on the waste line (with JW). Always reconcile vials drawn vs mg administered.

What administration CPT do I use for Fabrazyme?

CPT 96365 for the first hour, then 96366 for each additional hour (max 8 hours total). Initial Fabrazyme infusions run 2–4 hours at the maximum 0.25 mg/min rate. Once tolerability is established, infusion time can be reduced. Do NOT bill 96413 (chemo IV) — Fabrazyme is non-chemo enzyme replacement therapy.

Do I bill JZ or JW for Fabrazyme?

Both, depending on the day. Vials are fixed at 5 mg and 35 mg; dosing is 1 mg/kg. Most patient weights produce some discarded mg — bill JW with the discarded units on a separate line. When the math truly produces zero waste (e.g., 70 kg patient using two 35 mg vials), bill JZ. CMS has required one or the other on every single-dose-container drug claim since July 1, 2023.

What is the Medicare reimbursement for J0180?

For Q2 2026, the Medicare Part B payment limit for J0180 is $227.580 per mg (ASP + 6%). A 70 mg dose reimburses at approximately $15,930.60 per infusion; a 50 mg dose at approximately $11,379.00. Annualized cost (Medicare ASP+6%, 26 doses/year at q2wk for a 70 kg patient): approximately $414,196. Sequestration (~2%) reduces actual paid to roughly ASP + 4.3%.

Does Fabrazyme need premedication?

Premedication is recommended in clinical practice but not formally required by the FDA label. Most centers give acetaminophen + diphenhydramine (and sometimes a corticosteroid such as methylprednisolone) 30–60 minutes before each infusion to mitigate infusion-associated reactions. About half of patients experience IARs; antibody formation against agalsidase beta is common (most patients seroconvert within 3–6 months) and may worsen reactions or reduce efficacy.

How does Fabrazyme compare to Elfabrio and Galafold?

Three Fabry disease therapies are FDA-approved in the US. Fabrazyme (agalsidase beta, J0180, Sanofi Genzyme) is the original ERT — IV q2wk, suitable for any GLA mutation, lifelong therapy. Elfabrio (pegunigalsidase alfa-iwxj, J0219, Chiesi/Protalix, FDA-approved May 2023) is a newer PEGylated ERT — IV q2wk, designed for longer plasma half-life and reduced antibody formation. Galafold (migalastat, oral, pharmacy benefit) is a chaperone therapy taken every other day — only works for the ~30–50% of patients with "amenable" GLA missense mutations confirmed by an FDA-validated assay. Replagal (agalsidase alfa, Takeda) is approved in Europe but is NOT FDA-approved in the US.

What ICD-10 code is used for Fabrazyme?

Primary ICD-10 is E75.21 — "Fabry (-Anderson) disease" (alpha-galactosidase A deficiency). Add secondary codes for documented organ involvement: cardiac (I42.x, I43, I49.x, I50.x), renal (N18.x by stage, R80.x for proteinuria), CNS (G93.89, I63.x, G45.x, G62.89), skin (L98.8 for angiokeratoma), eye (H18.9, H35.81), hearing (H90.x). Most major payers require evidence of multi-system involvement plus enzyme assay (low α-Gal A activity) plus GLA gene mutation analysis in the PA submission.

Source documents

1. DailyMed — FABRAZYME (agalsidase beta) Prescribing Information
   FDA-approved label (BLA 103979); pediatric expansion 2018
2. FDA Fabrazyme label PDF (s5135, 2018 pediatric expansion)
3. Sanofi — Fabrazyme HCP product site
   Manufacturer coding & coverage guidance, Sanofi 2025
4. Sanofi Patient Connection
   Patient assistance program (1-800-745-4447); Fabry rare-disease team
5. CMS — Medicare Part B Drug ASP Pricing File
   Q2 2026 quarterly file, effective April 1 – June 30, 2026
6. SEER CanMED — HCPCS J0180 reference
7. UnitedHealthcare — Lysosomal Storage Disorder Enzyme Replacement Therapies medical policy
8. Aetna CPB 0729 — Enzyme Replacement and Substrate Reduction Therapy for Lysosomal Storage Disorders
9. FDA National Drug Code Directory
   NDC verification: 58468-0040-01 (5 mg), 58468-0041-01 (35 mg)
10. Elfabrio HCP product site (Chiesi)
    Comparator ERT for Fabry disease; FDA approval May 2023
11. Galafold HCP product site (Amicus Therapeutics)
    Oral chaperone for amenable GLA mutations
12. NEJM — BALANCE phase 3 trial: pegunigalsidase alfa vs agalsidase beta in Fabry disease (2023)
13. AAN/EFNS Fabry disease guidelines
    Fabry Outcome Survey (FOS) data referenced for clinical context

About this page

We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 2, 2026 — Initial publication. ASP data: Q2 2026. Manufacturer source: Sanofi 2025. FDA label: BLA 103979 (Apr 2003) with 2018 pediatric labeling expansion. Class comparison includes Elfabrio (May 2023 FDA approval) and Galafold (Aug 2018 FDA approval).

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indication and pediatric eligibility are verified against the current FDA label revision. We do not paraphrase from billing-software vendor blogs.